SANOFI (SNW.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:SNW - FR0000120578 - Common Stock
78.02 EUR
-1 (-1.27%)
Overall SNW gets a fundamental rating of 4 out of 10. We evaluated SNW against 54 industry peers in the Pharmaceuticals industry. SNW has an excellent profitability rating, but there are concerns on its financial health. SNW has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
- In the past year SNW was profitable.
- Each year in the past 5 years SNW has been profitable.
- Each year in the past 5 years SNW had a positive operating cash flow.
1.2 Ratios
- With a decent Return On Assets value of 10.63%, SNW is doing good in the industry, outperforming 79.63% of the companies in the same industry.
- Looking at the Return On Equity, with a value of 18.84%, SNW is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
- The Return On Invested Capital of SNW (13.40%) is better than 68.52% of its industry peers.
- SNW had an Average Return On Invested Capital over the past 3 years of 7.31%. This is significantly below the industry average of 13.93%.
- The last Return On Invested Capital (13.40%) for SNW is above the 3 year average (7.31%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.63% | ||
| ROE | 18.84% | ||
| ROIC | 13.4% |
ROA(3y)5.02%
ROA(5y)6.2%
ROE(3y)8.55%
ROE(5y)10.84%
ROIC(3y)7.31%
ROIC(5y)7.07%
1.3 Margins
- Looking at the Profit Margin, with a value of 20.63%, SNW belongs to the top of the industry, outperforming 81.48% of the companies in the same industry.
- SNW's Profit Margin has improved in the last couple of years.
- SNW has a Operating Margin of 23.61%. This is comparable to the rest of the industry: SNW outperforms 59.26% of its industry peers.
- In the last couple of years the Operating Margin of SNW has grown nicely.
- SNW's Gross Margin of 72.29% is in line compared to the rest of the industry. SNW outperforms 55.56% of its industry peers.
- In the last couple of years the Gross Margin of SNW has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.61% | ||
| PM (TTM) | 20.63% | ||
| GM | 72.29% |
OM growth 3Y-2.73%
OM growth 5Y1.75%
PM growth 3Y-7.54%
PM growth 5Y11.4%
GM growth 3Y0.71%
GM growth 5Y0.58%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so SNW is still creating some value.
- Compared to 1 year ago, SNW has about the same amount of shares outstanding.
- The number of shares outstanding for SNW remains at a similar level compared to 5 years ago.
- Compared to 1 year ago, SNW has an improved debt to assets ratio.
2.2 Solvency
- A Debt/Equity ratio of 0.18 indicates that SNW is not too dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.18, SNW is in the better half of the industry, outperforming 79.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | N/A | ||
| Altman-Z | N/A |
ROIC/WACC1.74
WACC7.71%
2.3 Liquidity
- SNW has a Current Ratio of 1.06. This is a normal value and indicates that SNW is financially healthy and should not expect problems in meeting its short term obligations.
- SNW has a Current ratio of 1.06. This is in the lower half of the industry: SNW underperforms 68.52% of its industry peers.
- A Quick Ratio of 0.30 indicates that SNW may have some problems paying its short term obligations.
- SNW has a worse Quick ratio (0.30) than 87.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.06 | ||
| Quick Ratio | 0.3 |
3. Growth
3.1 Past
- The earnings per share for SNW have decreased by -5.35% in the last year.
- Measured over the past 5 years, SNW shows a small growth in Earnings Per Share. The EPS has been growing by 5.10% on average per year.
- Looking at the last year, SNW shows a small growth in Revenue. The Revenue has grown by 2.56% in the last year.
- SNW shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.31% yearly.
EPS 1Y (TTM)-5.35%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%1.75%
Revenue 1Y (TTM)2.56%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-7.47%
3.2 Future
- SNW is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.41% yearly.
- Based on estimates for the next years, SNW will show a small growth in Revenue. The Revenue will grow by 4.47% on average per year.
EPS Next Y2.24%
EPS Next 2Y4.91%
EPS Next 3Y5.19%
EPS Next 5Y7.41%
Revenue Next Year-0.09%
Revenue Next 2Y3.14%
Revenue Next 3Y4.36%
Revenue Next 5Y4.47%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 10.27, the valuation of SNW can be described as very reasonable.
- SNW's Price/Earnings ratio is rather cheap when compared to the industry. SNW is cheaper than 87.04% of the companies in the same industry.
- SNW's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.94.
- A Price/Forward Earnings ratio of 9.23 indicates a reasonable valuation of SNW.
- Based on the Price/Forward Earnings ratio, SNW is valued cheaper than 83.33% of the companies in the same industry.
- SNW is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.94, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.27 | ||
| Fwd PE | 9.23 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of SNW indicates a somewhat cheap valuation: SNW is cheaper than 74.07% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 10.38 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates SNW does not grow enough to justify the current Price/Earnings ratio.
- SNW has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)4.59
PEG (5Y)2.01
EPS Next 2Y4.91%
EPS Next 3Y5.19%
5. Dividend
5.1 Amount
- No dividends for SNW!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:SNW (1/20/2026, 7:00:00 PM)
78.02
-1 (-1.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-24 2025-10-24/bmo
Earnings (Next)01-29 2026-01-29/amc
Inst Owners46.74%
Inst Owner ChangeN/A
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap188.44B
Revenue(TTM)66.91B
Net Income(TTM)13.80B
Analysts79.31
Price Target101.29 (29.83%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend3.79
Dividend Growth(5Y)4.3%
DP34.36%
Div Incr Years6
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.79%
Min EPS beat(2)-2.29%
Max EPS beat(2)5.86%
EPS beat(4)2
Avg EPS beat(4)1.85%
Min EPS beat(4)-2.29%
Max EPS beat(4)6.02%
EPS beat(8)5
Avg EPS beat(8)3.19%
EPS beat(12)7
Avg EPS beat(12)2.67%
EPS beat(16)11
Avg EPS beat(16)3.3%
Revenue beat(2)0
Avg Revenue beat(2)-0.96%
Min Revenue beat(2)-1.3%
Max Revenue beat(2)-0.63%
Revenue beat(4)0
Avg Revenue beat(4)-1.95%
Min Revenue beat(4)-4.57%
Max Revenue beat(4)-0.63%
Revenue beat(8)2
Avg Revenue beat(8)-1%
Revenue beat(12)4
Avg Revenue beat(12)9.01%
Revenue beat(16)8
Avg Revenue beat(16)21.12%
PT rev (1m)-5.69%
PT rev (3m)-7.55%
EPS NQ rev (1m)2.75%
EPS NQ rev (3m)-7.69%
EPS NY rev (1m)-0.13%
EPS NY rev (3m)-1.81%
Revenue NQ rev (1m)0.85%
Revenue NQ rev (3m)0.05%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.33%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.27 | ||
| Fwd PE | 9.23 | ||
| P/S | 2.82 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.57 | ||
| P/tB | 42.87 | ||
| EV/EBITDA | 10.38 |
EPS(TTM)7.6
EY9.74%
EPS(NY)8.45
Fwd EY10.83%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS27.7
BVpS30.33
TBVpS1.82
PEG (NY)4.59
PEG (5Y)2.01
Graham Number72.02
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.63% | ||
| ROE | 18.84% | ||
| ROCE | 16.17% | ||
| ROIC | 13.4% | ||
| ROICexc | 14.75% | ||
| ROICexgc | 65.74% | ||
| OM | 23.61% | ||
| PM (TTM) | 20.63% | ||
| GM | 72.29% | ||
| FCFM | N/A |
ROA(3y)5.02%
ROA(5y)6.2%
ROE(3y)8.55%
ROE(5y)10.84%
ROIC(3y)7.31%
ROIC(5y)7.07%
ROICexc(3y)8.13%
ROICexc(5y)7.97%
ROICexgc(3y)35.39%
ROICexgc(5y)35.54%
ROCE(3y)8.84%
ROCE(5y)8.55%
ROICexgc growth 3Y-13.63%
ROICexgc growth 5Y-1.43%
ROICexc growth 3Y-1.55%
ROICexc growth 5Y2.05%
OM growth 3Y-2.73%
OM growth 5Y1.75%
PM growth 3Y-7.54%
PM growth 5Y11.4%
GM growth 3Y0.71%
GM growth 5Y0.58%
F-ScoreN/A
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.68 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.06 | ||
| Quick Ratio | 0.3 | ||
| Altman-Z | N/A |
F-ScoreN/A
WACC7.71%
ROIC/WACC1.74
Cap/Depr(3y)73.02%
Cap/Depr(5y)67.36%
Cap/Sales(3y)6.35%
Cap/Sales(5y)5.97%
Profit Quality(3y)113.82%
Profit Quality(5y)104.22%
High Growth Momentum
Growth
EPS 1Y (TTM)-5.35%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%1.75%
EPS Next Y2.24%
EPS Next 2Y4.91%
EPS Next 3Y5.19%
EPS Next 5Y7.41%
Revenue 1Y (TTM)2.56%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-7.47%
Revenue Next Year-0.09%
Revenue Next 2Y3.14%
Revenue Next 3Y4.36%
Revenue Next 5Y4.47%
EBIT growth 1Y9.12%
EBIT growth 3Y1.33%
EBIT growth 5Y5.12%
EBIT Next Year29.1%
EBIT Next 3Y13.19%
EBIT Next 5Y10.5%
FCF growth 1Y-19.94%
FCF growth 3Y-11.46%
FCF growth 5Y-0.14%
OCF growth 1Y-11.47%
OCF growth 3Y-4.79%
OCF growth 5Y3.31%
SANOFI / SNW.DE FAQ
Can you provide the ChartMill fundamental rating for SANOFI?
ChartMill assigns a fundamental rating of 4 / 10 to SNW.DE.
What is the valuation status of SANOFI (SNW.DE) stock?
ChartMill assigns a valuation rating of 5 / 10 to SANOFI (SNW.DE). This can be considered as Fairly Valued.
How profitable is SANOFI (SNW.DE) stock?
SANOFI (SNW.DE) has a profitability rating of 7 / 10.
Can you provide the financial health for SNW stock?
The financial health rating of SANOFI (SNW.DE) is 3 / 10.
What is the earnings growth outlook for SANOFI?
The Earnings per Share (EPS) of SANOFI (SNW.DE) is expected to grow by 2.24% in the next year.